Search

Hydrogen (H

With the rapid development of renewable and sustainable energy, biogas upgrading for producing high-quality biomethane as an alternative to natural gas has attracted worldwide attention. This paper comprehensively reviews the current state of biogas upgrading technologies. The advances in physicochemical, photosynthetic autotrophic, and chemical autotrophic biogas upgrading technologies are briefly described with particular attention to the key challenges. New chemical autotrophic biogas upgrading strategies, such as direct and indirect exogenous hydrogen supply, for overcoming barriers to biogas upgrading and realizing highly efficient bioconversion of carbon dioxide are summarized. For each approach to exogenous hydrogen supply for biogas upgrading, the key findings and technical limitations are summarized and critically analyzed. Finally, future developments are also discussed to provide a reference for the development of biogas upgrading technology that can address the global energy crisis and climate change issues related to the application of biogas.

As a clean and renewable energy, bioenergy is one of the most promising alternatives to fossil fuels. Lignocellulose possesses great potential for bioenergy production, but the recalcitrant and heterogeneous structure limits its application. Pretreatment technology offers an effective solution to fractionate the main components of the lignocellulose and uncover the available cellulose. The obtained feedstock can be applied to bioconversion into energy, e.g., bioethanol, biogas, biohydrogen, etc. Here, the current state of lignocellulose pretreatment technologies was comprehensively reviewed, the advances in bioenergy production from pretreated lignocellulose was described, with particular attention to key challenges involved. Several new strategies for overcoming pretreatment barriers to realize highly efficient lignocellulose bioconversion were highlighted. The insights given in this review will facilitate further development on lignocellulosic bioenergy production, towards addressing the global energy crisis and climate change related to the use of fossil fuels.

Ovarian cancer (OC) is the commonest cause of gynaecological cancer-associated death because of the wide metastasis and frequent recidivation. JTC-801 is a new synthetic compound with the function of reversing pain and anxiety symptoms as a selective opioid receptor-like1 receptor (belonging to the G-protein-coupled receptor) antagonist. We investigated the role and possible mechanisms of JTC-801 in the cell growth and metastasis of OC. It was observed that JTC-801 inhibited the proliferation, invasion and migration of cancer in SKOV3 cells. The apoptosis rate of SKOV3 cells treated with JTC-801 was significantly increased (P0.05), and the expression results of relevant apoptosis proteins (BCL2, BAX, Active Caspase-3) indicated the JTC-801 could induce the apoptosis of SKOV3. Further, the expression levels of phosphorylated AKT, phosphorylated mTOR, P70 and CyclinD1 in the PI3K/AKT signaling pathway were obviously reduced in the JTC-801 treated SKOV3 group. This suggests that JTC-801 exerts its anticancer effect through the PI3K/AKT signaling pathway. Our data also highlights the possibility of using JTC-801 as a novel therapeutic drug for OC treatment mean while it plays the analgesic effect.